No Patent, No Pharma: Who Actually Funds Hypnosis Research?

Who Actually Funds Hypnosis Research, and Why Isn't Pharma at the Table?

An unbalanced scale illustrating the clinical research funding gap: a heavy money bag labeled "Patented Drug R&D, ~$1.3B per approval" weighs down one side, while a light pan labeled "Hypnosis Research, No patent, no sponsor" barely tips the other.

A year ago, this blog looked at what's happening in clinical hypnosis research, real trials, registered on ClinicalTrials.gov, showing measurable effects on pain, sleep, and anxiety. Revisiting that ground a year later raises a different question, one the original post didn't ask: who is actually paying for this?

The answer, almost without exception, is: not the pharmaceutical industry. And the reason isn't scientific doubt about whether hypnosis works - the evidence base, while still developing, is genuinely there. The reason is economics.

The pattern is consistent, and it's not a coincidence

Look at the sponsor field on almost any hypnosis RCT and a pattern repeats. The chronic-pain hypnosis trial in cancer survivors cited in our original post was funded by NIH grants through the National Institute of Nursing Research and the National Center for Complementary and Integrative Health, not by a pharmaceutical sponsor. The newer spinal cord injury pain trial published in Neurology in 2026 was academically led, out of the University of Washington. The diabetes self-management trial (HypnoDiaCare) was sponsored by a university, not an industry partner. This isn't a handful of unlucky examples, it's close to the entire field.

Compare that to how a typical industry-sponsored drug trial is funded, and the contrast is stark. Phase III drug trials commonly run into the tens of millions of dollars per study, with total R&D cost per approved drug estimated at $1.3 billion when failures are factored in. Sponsors accept that cost because a successful trial ends in a patent - 20 years of market exclusivity that lets them recoup the investment and then some.

Hypnosis has no equivalent endpoint. There is no molecule to patent, no delivery device to exclusively license, no proprietary formulation. A hypnosis protocol, once published, can be replicated by any trained clinician anywhere. That's exactly what makes it valuable to a patient and valueless as a commercial asset. The two are the same fact viewed from opposite sides.

This isn't unique to hypnosis

The same funding gap applies to a broader category of interventions: behavioral therapies, many botanicals and dietary interventions, and other non-patentable approaches sometimes grouped loosely as BADs (botanicals, adjuncts, and dietary interventions). Sleep hygiene protocols, mindfulness-based interventions, and dietary supplement research all share the same structural problem hypnosis has - real evidence, no IP, no commercial sponsor with a reason to fund a large confirmatory trial.

This is worth naming clearly, because it reframes the question. It's not "is hypnosis legitimate enough for serious research funding" - the Neurology publication alone answers that. It's "what funding model works for genuinely effective interventions that will never generate patent revenue." That's a much bigger question than hypnosis alone, and it's one clinical research as a field hasn't solved.

A different model: patient-controlled data instead of sponsor-controlled trials

One direction worth exploring seriously: shifting some of the infrastructure cost away from centralized trial funding altogether, toward models where patients themselves hold and control the data that would otherwise require a expensively-run, centrally-funded trial to generate.

Patient-controlled health passports and health data cooperatives — models where individuals maintain their own longitudinal health data and choose when and with whom to share it — could let interested participants opt into structured, ongoing outcome tracking for interventions like hypnosis without requiring a sponsor to underwrite a traditional RCT infrastructure from scratch. Real-world, patient-consented longitudinal data won't replace the rigor of a randomized trial, but it could substantially lower the cost of generating the kind of practical evidence that non-patentable interventions currently struggle to fund at scale. This connects to a broader theme worth returning to on this blog: who owns clinical data, and what becomes possible when patients — not sponsors — decide how it's used for research.

Organizations worth knowing about

If not pharma, then who might be interested? I don't know whether any of the following organizations fund research, co-fund it, or have any appetite to. I have no evidence either way, and this list isn't a claim about their funding activity. What I can say is that most of them were unfamiliar to me before researching this post, and I suspect that's true for most readers outside the hypnosis field too. A country like Switzerland already has a notable concentration of hypnosis clinical societies and academic research capacity, which at minimum makes it a reasonable place to start looking and asking:

  • SMSH Swiss Medical Society of Hypnosis smsh.ch
  • GHypS Society for Clinical Hypnosis Switzerland hypnose.ch
  • IRHyS Institut Romand d'Hypnose Suisse, the French-speaking Swiss society irhys.ch
  • ESH European Society of Hypnosis, the umbrella body all three Swiss societies belong to as constituent members esh-hypnosis.eu
  • ISH International Society of Hypnosis, the global umbrella organization ishhypnosis.org
  • MEG the Milton H. Erickson Society for Clinical Hypnosis in Germany meg-hypnose.de

Academic centers are part of the same picture. Swiss hypnosis research already has a foothold at CHUV Lausanne and the University of Zurich, the same institution whose research prompted the original post in this series. Whether any of this adds up to a viable funding pathway for hypnosis research is an open question, not something this post can answer, but it's a question worth someone asking directly, and a data-cooperative or patient-directed research model may be one way to make that question easier to act on.

Sources

Disclaimer: This article is an educational discussion prepared for informational purposes. It does not constitute financial, legal, or research funding advice. Funding structures and sponsor affiliations for specific trials should be verified directly on ClinicalTrials.gov or the relevant registry before citing them elsewhere.

Comments

Post a Comment

Popular posts from this blog

Project Management Software

What is a Project Management System or Project Management Software?  Is there a common understanding on functionality of such system and if it is needed at all?  What systems project managers use for projects? Project Management System should be one to help Project Managers to manage Projects. The word " project " originally meant "before an action" or plan of something. Projects are defined by  PMI  as Temporary endeavor (having start and end) to create a unique product, service or result. Project managers are to manage timelines, budget and scope.  PMI   defines 5 process groups (from start to end) and 10 knowledge areas. Project Management Software definition in Wikipedia is vague and open to interpretations: Project management software has the capacity to help plan, organize, and manage resource tools and develop resource estimates. Depending on the sophistication of the software, it can manage estimation and planning, scheduling, cost contro...
Read more

Making Unaccounted Costs Accountable in Clinical Research

Image
Clinical trials operate under strict timelines, regulatory requirements, and complex coordination between sponsors, CROs, sites, and vendors. When delays occur or issues arise, project teams often resolve problems by working longer hours rather than by adjusting timelines, budgets, or processes. In many organizations, a standard working day is approximately eight hours. However, Clinical Research Associates, Project Managers, and other clinical operations staff may regularly work ten or more hours per day, especially during critical study phases. If only eight hours are recorded in time sheets while ten hours are actually worked, two hours per day become unaccounted operational effort . Individually, this may appear minor. Over the duration of a clinical trial, the financial impact can be substantial. Financial Example: Unaccounted Hours Over a Project Duration
Read more

Clinical Research on Hypnosis: Evidence and Applications

Image
* This image is produced by GenAI as Illustration, it may contains irregularities.  Recently, I came across new research from the University of Zurich that looked at the effects of hypnosis on the brain. I remembered hearing about hypnosis in the past, but I had never followed the subject closely. Like many, I assumed it was something on the edge of science Interesting, but not really part of how we understand the human body or behavior in practical terms. It’s not something you’ll find in a physiology textbook, and it doesn’t fit into the structured way we usually think about biology, medicine, or professional life. What caught my attention this time was the growing number of clinical studies showing that hypnosis can help with real-world problems. Especially sleep, chronic pain, and anxiety. These are not isolated cases. There’s now enough consistent data to suggest that hypnosis has measurable effects, and that it might be underused simply because it doesn’t fit into the usual...
Read more